Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4] triazol-3-yl)pyridine-2-carbonitrile (FYX-051): A new xanthine oxidoreductase inhibitor

Drug Metabolism and Disposition

Volumn 35, Issue 12, 2007, Pages 2143-2148

  Omura, Koichi ^a   Nakazawa, Takashi ^a   Sato, Takahiro ^a   Iwanaga, Takashi ^a   Nagata, Osamu ^a  

^a Fuji Yakuhin Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (5 PYRIDIN 4 YL 1H [1,2,4]TRIAZOL 3 YL)PYRIDINE 2 CARBONITRILE 2; FYX 051; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; ISOENZYME; MEFENAMIC ACID; PROPOFOL; RECOMBINANT ENZYME; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE OXIDASE INHIBITOR;

ARTICLE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

ANIMALS; BACULOVIRIDAE; BILIRUBIN; BIOTRANSFORMATION; CELL LINE; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INSECTS; INTESTINES; ISOENZYMES; KINETICS; MEFENAMIC ACID; MICROSOMES, LIVER; NITRILES; PROPOFOL; PYRIDINES; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; XANTHINE DEHYDROGENASE;

EID: 36348934031     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017251     Document Type: Article

References (26)

1. Albert C, Vallée M, Beaudry G, Bélanger A, and Hum DW (1999) The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292-3302.
2. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, and Jansen PL (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964.
3. Burchell B, Brierley CH, and Rance D (1995) Specificity of human UDP-glucuronosyltransferase and xenobiotic glucuronidation. Life Sci 57:1819-1831.
4. Fujiwara R, Nakajima M, Yamanaka H, Nakamura A, Katoh M, Ikushiro S, Sakaki T, and Yokoi T (2007) Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747-757.
5. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, and Zbaida S (2004) Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 32:267-271.
6. Green MD and Tephly TR (1998) Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26:860-867.
7. Huskey SW, Doss GA, Miller RR, Schoen WR, and Chiu SH (1994a) N-Glucuronidation reactions. II. Relative N-glucuronidation reactivity of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole in rat, monkey, and human hepatic microsomes. Drug Metab Dispos 22:651-658.
8. Huskey SW, Magdalou J, Ouzzine M, Siest G, and Chiu SH (1994b) N-Glucuronidation reactions. III. Regioselectivity of N-glucuronidation of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole using human and rat recombinant UDP-glucuronosyltransferases stably expressed in V79 cells. Drug Metab Dispos 22:659-662.
9. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, et al. (2003) Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306:688-693.
10. King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, and Tephly TR (1996) The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 332:92-100.
11. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, and Courtney R (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48:3543-3551.
12. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
13. McGurk KA, Brierley CH, and Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012.
14. McGurk KA, Remmel RP, Hosagrahara VP, Tosh D, and Burchell B (1996) Reactivity of mefenamic acid 1-O-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab Dispos 24:842-849.
15. Nakazawa T, Miyata K, Omura K, Iwanaga T, and Nagata O (2006) Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2- carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides. Drug Metab Dispos 34:1880-1886.
16. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
17. Smith JN and Williams RT (1949) Studies in detoxication. 23. The fate of aniline in the rabbit. Biochem J 44:242-250.
18. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
19. Strassburg CP, Manns MP, and Tukey RH (1998) Expression of the UDP-glucuronosyltransferase 1A locus in human colon: identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 273:8719-8726.
20. Tachibana M, Tanaka M, Masubuchi Y, and Horie T (2005) Acyl glucuronidation of fluoroquinolone antibiotics by the UDP- glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos 33:803-811.
21. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
22. Villeneuve L, Girard H, Fortier LC, Gagne JF, and Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128.
23. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, and Wrighton SA (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.
24. Wynalda MA, Wynalda KM, Amore BM, Fagermess PE, and Wienkers LC (2003) Characterization of bropirimine O-glucuronidation in human liver microsomes. Xenobiotica 33:999-1011.
25. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, and Yokoi T (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329-332.
26. Yan Z, Caldwell GW, Gauthier D, Leo GC, Mei J, Ho CY, Jones WJ, Masucci JA, Tuman RW, Galemmo RA Jr, et al. (2006) N-Glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)-(3-fluorophenyl) -amine by human UDP-glucuronosyltransferases. Drug Metab Dispos 34:748-755.